Janine Haug

948 total citations
10 papers, 529 citations indexed

About

Janine Haug is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Janine Haug has authored 10 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Janine Haug's work include Multiple Myeloma Research and Treatments (6 papers), Cancer Mechanisms and Therapy (4 papers) and Cell death mechanisms and regulation (2 papers). Janine Haug is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Cancer Mechanisms and Therapy (4 papers) and Cell death mechanisms and regulation (2 papers). Janine Haug collaborates with scholars based in United States, Germany and United Kingdom. Janine Haug's co-authors include S. Vincent Rajkumar, Shaji Kumar, Michael Timm, Teresa K. Kimlinger, Philip R. Greipp, Thomas E. Witzig, Vijay Ramakrishnan, John A. Lust, Michael Kline and Rafaël Fonseca and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Janine Haug

9 papers receiving 520 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janine Haug United States 7 392 206 197 71 65 10 529
Alma Jenkins United Kingdom 10 405 1.0× 113 0.5× 179 0.9× 31 0.4× 67 1.0× 10 493
Homare Eda United States 13 815 2.1× 364 1.8× 480 2.4× 61 0.9× 48 0.7× 29 1.0k
Luigia Rao Italy 8 227 0.6× 179 0.9× 158 0.8× 31 0.4× 55 0.8× 10 390
Andrej Bešše Switzerland 12 501 1.3× 78 0.4× 99 0.5× 46 0.6× 49 0.8× 35 636
Claude Clément France 8 211 0.5× 169 0.8× 239 1.2× 43 0.6× 155 2.4× 8 520
Erika Serrano Spain 5 418 1.1× 35 0.2× 200 1.0× 33 0.5× 61 0.9× 5 604
Lourdes Mendez United States 10 309 0.8× 104 0.5× 218 1.1× 191 2.7× 190 2.9× 34 609
Mike Zhong China 6 357 0.9× 516 2.5× 566 2.9× 39 0.5× 206 3.2× 21 881
Linda W. Horton United States 9 253 0.6× 118 0.6× 239 1.2× 144 2.0× 175 2.7× 12 595
Fátima Solange Pasini Brazil 13 223 0.6× 30 0.1× 165 0.8× 48 0.7× 63 1.0× 31 444

Countries citing papers authored by Janine Haug

Since Specialization
Citations

This map shows the geographic impact of Janine Haug's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janine Haug with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janine Haug more than expected).

Fields of papers citing papers by Janine Haug

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janine Haug. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janine Haug. The network helps show where Janine Haug may publish in the future.

Co-authorship network of co-authors of Janine Haug

This figure shows the co-authorship network connecting the top 25 collaborators of Janine Haug. A scholar is included among the top collaborators of Janine Haug based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janine Haug. Janine Haug is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
2.
Haug, Janine, et al.. (2025). Hyperphosphorescent OLEDs: Harnessing the Power of MR‐TADF Terminal Emitters. Advanced Optical Materials. 13(23). 3 indexed citations
3.
Ramakrishnan, Vijay, et al.. (2014). Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia. 28(7). 1519–1528. 43 indexed citations
4.
Ramakrishnan, Vijay, Stephen M. Ansell, Janine Haug, et al.. (2011). MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia. 26(2). 340–348. 60 indexed citations
5.
Ramakrishnan, Vijay, Michael Timm, Janine Haug, et al.. (2009). Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 29(8). 1190–1202. 73 indexed citations
6.
Kline, Michael, S. Vincent Rajkumar, Michael Timm, et al.. (2007). ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 21(7). 1549–1560. 129 indexed citations
7.
Timm, Michael, Teresa K. Kimlinger, Janine Haug, et al.. (2006). Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia. 20(10). 1863–1869. 18 indexed citations
8.
Kumar, Shaji, Philip R. Greipp, Janine Haug, et al.. (2006). Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 7621–7621. 1 indexed citations
9.
Kumar, Shaji, Thomas E. Witzig, Michael Timm, et al.. (2003). Expression of VEGF and its receptors by myeloma cells. Leukemia. 17(10). 2025–2031. 122 indexed citations
10.
Brown, Christopher, John F. DiPersio, Janine Haug, et al.. (1996). Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells.. Proceedings of the National Academy of Sciences. 93(20). 10785–10790. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026